The ALPL gene provides the blueprint for an enzyme called tissue-nonspecific alkaline phosphatase (TNSALP), which plays a central role in hardening bones and teeth by regulating mineral balance in the body. When mutations in ALPL reduce or eliminate this enzyme’s activity, the result is hypophosphatasia (HPP), a metabolic bone disease whose severity ranges from fatal in newborns to mildly bothersome in adults.1PubMed Central. Novel ALPL genetic alteration associated with an odontohypophosphatasia phenotype With more than 340 known ALPL mutations identified and inheritance patterns that include both dominant and recessive forms, the clinical picture is anything but simple.
What TNSALP Actually Does in the Body
TNSALP is expressed most strongly in bone, liver, and kidney, but its most clinically relevant job is in the skeleton.2PubMed. Alkaline phosphatase: Structure, expression and its function in bone mineralization The enzyme sits on the outer surface of tiny structures called matrix vesicles, which are released by bone-forming cells at sites where new bone needs to be laid down. There, TNSALP breaks down a molecule called pyrophosphate (PPi), which is one of the body’s built-in brakes on mineralization. Pyrophosphate directly blocks the formation of hydroxyapatite, the calcium-phosphate crystal that gives bone its hardness.3PubMed. Pyrophosphate: a key inhibitor of mineralisation By chewing up pyrophosphate and releasing inorganic phosphate in the process, TNSALP simultaneously removes an inhibitor and supplies a building block for mineral crystal growth.4Annals of Pediatric Endocrinology & Metabolism. Skeletal mineralization: mechanisms and diseases
Beyond bones, TNSALP has a less obvious but critical role in the brain. The enzyme is needed to convert pyridoxal 5′-phosphate (PLP, the active form of vitamin B6) into a form that can cross cell membranes. When TNSALP activity is very low, PLP cannot get into neurons efficiently. Since B6 is essential for making the inhibitory brain chemical GABA, infants with severe TNSALP deficiency can develop life-threatening seizures that respond only to vitamin B6 supplementation.5PubMed. Hypophosphatasia: Vitamin B(6) status of affected children and adults6PubMed Central. Vitamin B6 dependent seizures
How ALPL Mutations Cause Disease
Humans carry four alkaline phosphatase genes. Three of them produce tissue-specific versions of the enzyme found in the intestine, placenta, and germ cells, and their genes cluster on chromosome 2. ALPL, the gene encoding TNSALP, sits on chromosome 1.7PubMed Central. Alkaline phosphatase: an overview Structural studies have shown that TNSALP differs enough from the tissue-specific forms that it cannot pair with them to form functional dimers, meaning a loss of TNSALP cannot be compensated by the other alkaline phosphatases.8Journal of Biological Chemistry. Structural Evidence of Functional Divergence in Human Alkaline Phosphatases
Mutations in ALPL are overwhelmingly missense changes scattered throughout the gene. The inheritance pattern depends largely on how much enzyme activity a given mutation wipes out. Severe forms of HPP, those appearing around birth or in early infancy, follow autosomal recessive inheritance, meaning a child needs two defective copies of ALPL. Milder forms seen in older children and adults can be either recessive or autosomal dominant, where a single mutated copy is enough to cause symptoms.9PubMed. Genetics of hypophosphatasia
Some mutations go beyond simply reducing enzyme output by half. Certain variants exert what researchers call a dominant-negative effect: the abnormal protein actively interferes with the normal copy, dragging total enzyme activity well below 50 percent. One such variant, G129E, was shown to suppress the function of wild-type TNSALP when both were expressed together, meaning the mutant protein poisons the normal protein’s ability to work.10PubMed Central. A novel dominant negative variant of ALPL induces hypophosphatasia A separate Japanese family study documented another dominant-negative mutation (Gly82Arg) that completely abolished enzyme activity and suppressed the wild-type enzyme.11PubMed. Novel mutation in the ALPL gene with a dominant negative effect in a Japanese family These dominant-negative mutations help explain why some people with only one defective copy of ALPL still develop significant disease.
Clinical Spectrum of Hypophosphatasia
HPP is often described as having the widest severity range of any skeletal disease, and that is not an exaggeration. At the lethal end, perinatal and infantile forms carry extremely high mortality, with death rates reported between 50 and 100 percent, usually from respiratory failure caused by a severely undermineralized rib cage.12PubMed Central. Asfotase Alfa Treatment Improves Survival for Perinatal and Infantile Hypophosphatasia A retrospective study of 48 perinatal and infantile patients across seven countries found that the likelihood of surviving without invasive ventilation dropped to roughly 25 percent by age five. B6-dependent seizures and respiratory failure were strongly associated with early death in that group.13PubMed. Natural History of Perinatal and Infantile Hypophosphatasia: A Retrospective Study
Childhood forms tend to be less immediately life-threatening but still debilitating. A clinical series documented rickets-like deformities (bowed legs, frontal bossing, rachitic rosary along the ribs, scoliosis) in the majority of patients, along with joint hypermobility and low muscle tone. One of the most distinctive signs in children is the premature loss of baby teeth: teeth erupted normally around six to eight months of age, then started falling out just months later.14PubMed Central. Dental manifestations of hypophosphatasia in children and the effects of enzyme replacement therapy on dental status: A series of clinical cases The teeth fall out with their roots intact, which distinguishes HPP from ordinary early tooth loss due to cavities or trauma. An odontohypophosphatasia form exists where the teeth are essentially the only affected tissue, featuring short root anomaly and abnormal dentin or cementum formation.15BMC Oral Health. Current concepts in odontohypophosphatasia form of hypophosphatasia and report of two cases
At the mildest end, adult HPP often goes unrecognized for decades. Patients typically endure chronic pain, recurrent fractures (especially stress fractures of the metatarsals and femoral pseudofractures), and impaired quality of life that gets attributed to other conditions.16PubMed Central. Hypophosphatasia: clinical manifestation and burden of disease in adult patients One reported case involved a man in his fifties with recurrent fractures beginning in his forties, whose HPP diagnosis finally came when persistently low serum alkaline phosphatase levels were noticed alongside a heterozygous ALPL missense variant.17PubMed Central. Adult Hypophosphatasia in a Middle-Aged Patient With Recurrent Fractures: Prevention of New Fractures With Asfotase Alfa
Why HPP Gets Missed and the Bisphosphonate Trap
Diagnosis hinges on a finding that most clinicians are not trained to look for: persistently low serum alkaline phosphatase. Lab reports flag high alkaline phosphatase all the time because elevated levels can signal liver disease or bone turnover from fractures. Low values, on the other hand, rarely trigger an alert. A characteristic biochemical profile for HPP includes low serum alkaline phosphatase alongside elevated PLP (the active B6 metabolite) and elevated urinary phosphoethanolamine.18Mayo Clinic Proceedings. ALPL Gene: Function, Mutations, and Hypophosphatasia
Complicating matters, some patients with genetically confirmed HPP have total alkaline phosphatase levels that fall within the normal reference range. A case report showed that measuring bone-specific alkaline phosphatase, a more targeted test, was necessary to uncover the deficiency that total alkaline phosphatase missed.19PubMed Central. A Case of Hypophosphatasia With Normal Alkaline Phosphatase Levels This means an unknown number of HPP patients may have been overlooked simply because their routine lab work looked unremarkable.
The most consequential misdiagnosis involves treating HPP patients with bisphosphonates, which are widely prescribed for osteoporosis and other fragile-bone conditions. Bisphosphonates work partly by increasing pyrophosphate levels in bone, which is the opposite of what an HPP patient needs. Adults with HPP are already suffering from too much pyrophosphate blocking mineralization, so bisphosphonates can worsen the underlying defect. An emerging consensus holds that bisphosphonates should not be used in adults with HPP and low bone mass.20PubMed Central. Bisphosphonate Use and Fractures in Adults with Hypophosphatasia One case report described a patient initially misdiagnosed with osteogenesis imperfecta who was treated with bisphosphonates and subsequently developed atypical femoral fractures, a complication consistent with the drug worsening HPP’s mineralization defect.21PubMed Central. Atypical Fracture From Bisphosphonate Use in Hypophosphatasia With Improved Bone Response to Teriparatide Therapy
Enzyme Replacement Therapy With Asfotase Alfa
Until 2015, there was no approved treatment for HPP. Asfotase alfa (brand name Strensiq) changed that. It is a bone-targeted fusion protein that replaces the missing TNSALP enzyme activity. In children with HPP, a clinical trial showed significant radiographic improvement in bone mineralization at six months, with additional gains in growth, muscle strength, motor function, and quality of life that were sustained over five years of treatment. For most of those children, pain and disability resolved.22PubMed Central. Asfotase alfa therapy for children with hypophosphatasia
For the most severe perinatal and infantile forms, asfotase alfa has improved survival rates substantially. Before enzyme replacement was available, those forms were often fatal within the first year of life. Data from treatment trials showed enough improvement to earn regulatory approval specifically for perinatal, infantile, and juvenile-onset HPP in multiple countries.12PubMed Central. Asfotase Alfa Treatment Improves Survival for Perinatal and Infantile Hypophosphatasia
Adults with HPP also benefit, though the evidence base is newer. Registry data from adults treated with asfotase alfa for at least six months showed improvements in how far they could walk (the average distance on a six-minute walk test rose from about 400 meters at baseline to roughly 480 meters at one year), along with reductions in self-reported pain and gains in physical quality-of-life scores that were maintained over three years.23PubMed Central. Effectiveness of asfotase alfa for treatment of adults with hypophosphatasia: results from a global registry Asfotase alfa requires frequent subcutaneous injections, typically three or six times per week, which represents a significant burden and motivates the search for longer-lasting treatments.
Gene Therapy Research in Animal Models
Because enzyme replacement demands lifelong injections and cannot fully replicate the normal localized delivery of TNSALP, researchers have been exploring gene therapy as a potential one-time fix. The concept involves delivering a working copy of the ALPL gene using a viral vector so the body can produce TNSALP on its own. Studies in knockout mice, which completely lack TNSALP and normally die within about ten to twelve days after birth, have been encouraging.
One line of research used adeno-associated virus serotype 8 (AAV8) to deliver a bone-targeted version of TNSALP (called TNAP-D10) via a single intramuscular injection. Treated knockout mice survived to the study endpoint at 70 days without developing seizures, showed grossly normal skeletal development on X-ray, and had normal tooth formation including restored cementum and periodontal ligament attachment. No unwanted calcification appeared in the kidneys, aorta, coronary arteries, or brain.24PubMed Central. Gene Therapy Using Adeno-Associated Virus Serotype 8 Encoding TNAP-D(10) Improves the Skeletal and Dentoalveolar Phenotypes in Alpl(-/-) Mice
An earlier study using a similar AAV8 approach tested multiple forms of TNSALP. A single intravenous injection of a bone-targeted form into newborn knockout mice prolonged survival and produced healthy-appearing animals with mature bone mineralization on X-ray. Interestingly, even a non-bone-targeted soluble form of the enzyme showed some survival benefit, suggesting that simply having enough TNSALP circulating in the blood may be sufficient to correct much of the disease.25PubMed Central. Rescue of severe infantile hypophosphatasia mice by AAV-mediated sustained expression of soluble alkaline phosphatase No human gene therapy trial for HPP has been reported yet, but these results are generating real optimism in the field.
TNSALP and Vascular Calcification
While too little TNSALP causes bones to stay soft, there is growing evidence that too much of it in the wrong tissues can cause arteries to harden. In healthy adults, blood vessel walls do not express much TNSALP. But in conditions like chronic kidney disease and atherosclerosis, smooth muscle cells in artery walls start ramping up TNSALP expression. This strips away the pyrophosphate that normally protects arteries from calcifying and essentially turns vessel walls into bone-like tissue.
To prove this was not just a coincidence, researchers created mice that overexpress TNSALP in vascular smooth muscle cells. Male mice in that model developed massive arterial calcification, high blood pressure, and enlargement of the heart, with a median lifespan of just 44 days. Promisingly, treating these mice with a TNSALP inhibitor called SBI-425 reduced aortic calcification and cardiac enlargement and extended their lives, all without affecting the skeleton.26PubMed Central. Pathophysiological role of vascular smooth muscle alkaline phosphatase in medial artery calcification A separate experiment that overexpressed TNSALP in the endothelial lining of arteries produced generalized arterial calcification, elevated blood pressure, and compensatory thickening of the left heart ventricle by 23 weeks of age.27PubMed Central. Transgenic Overexpression of Tissue-Nonspecific Alkaline Phosphatase (TNAP) in Vascular Endothelium Results in Generalized Arterial Calcification
This creates a therapeutic paradox. Treating HPP means boosting TNSALP activity to strengthen bones, but globally increasing the enzyme could theoretically promote arterial calcification. It is one reason that bone-targeted forms of TNSALP, like the D10-tagged version used in gene therapy experiments, are designed to concentrate their activity at the skeleton rather than flooding the bloodstream. The development of selective TNSALP inhibitors for cardiovascular disease and bone-targeted TNSALP replacement for HPP are essentially two sides of the same coin, both relying on the same enzyme but pushing it in opposite directions for different tissues.
Dental Signs as an Early Diagnostic Clue
One of the most underappreciated features of HPP is what it does to teeth, and dental symptoms sometimes provide the earliest or only clue that something is wrong. In children, the hallmark is premature loss of deciduous (baby) teeth, often before age two, with intact roots still attached. This happens because HPP impairs the formation of cementum, the thin layer of mineralized tissue that anchors tooth roots into the jawbone via the periodontal ligament. Without proper cementum, the teeth are poorly anchored and fall out with little or no trauma.14PubMed Central. Dental manifestations of hypophosphatasia in children and the effects of enzyme replacement therapy on dental status: A series of clinical cases
Adults with milder HPP may present with short root anomalies in permanent teeth, or a history of unexpectedly early tooth loss. The odontohypophosphatasia form of the disease can present with dental problems as the sole clinical finding, making it easy to dismiss as bad luck or poor dental health unless a dentist or physician thinks to check alkaline phosphatase levels.15BMC Oral Health. Current concepts in odontohypophosphatasia form of hypophosphatasia and report of two cases For families with young children losing teeth early, this is worth bringing to a doctor’s attention. A simple blood test for alkaline phosphatase can be the first step toward a diagnosis that explains much more than the teeth.
Living With Mild or Adult-Onset HPP
For people with milder forms, the daily reality of HPP is often less about dramatic skeletal crises and more about a chronic, grinding burden of musculoskeletal pain, fatigue, and fractures that do not heal well. Adults with HPP frequently report that their symptoms were dismissed for years, attributed to fibromyalgia, chronic fatigue syndrome, or simply aging. The recurrent stress fractures, particularly metatarsal fractures in the feet and lateral femoral fractures in the thigh, tend to be the feature that eventually sends someone down the diagnostic path.16PubMed Central. Hypophosphatasia: clinical manifestation and burden of disease in adult patients
Exercise, weight management, and adequate nutrition remain important for bone health in HPP, but the usual advice about calcium and vitamin D supplementation needs to be carefully calibrated. People with HPP are not lacking the raw materials for bone; they are lacking the enzyme that allows those materials to be deposited correctly. Oversupplementing calcium in someone whose bones cannot properly mineralize risks pushing calcium into places it does not belong, like soft tissues. Decisions about supplements and bone medications need to be made with a specialist who understands HPP, ideally an endocrinologist or metabolic bone disease expert familiar with the condition. Given how uncommon the diagnosis is, many patients travel to specialized centers for their care.